ARTICLE | Finance
Soft Impact
Why buysiders are lukewarm on Celgene’s acquisition of Impact
January 13, 2018 12:19 AM UTC
Underwhelmed by the proposed acquisition of Impact Biomedicines Inc. by Celgene Corp. (NASDAQ:CELG), buysiders hope to see the big biotech further expand its revenue base beyond Revlimid lenalidomide through additional deals in the near term.
“Celgene has to address the future Revlimid patent cliff which has been exacerbated after recent late-stage pipeline setbacks,” said Ailsa Craig of International Biotechnology Trust plc. ...